{"id":"NCT01877668","sponsor":"Pfizer","briefTitle":"Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-20","primaryCompletion":"2015-12-18","completion":"2015-12-18","firstPosted":"2013-06-14","resultsPosted":"2017-07-06","lastUpdate":"2017-07-06"},"enrollment":422,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"Tofacitinib 5 mg BID","otherNames":[]},{"type":"DRUG","name":"Tofacitinib 10 mg BID","otherNames":[]},{"type":"DRUG","name":"Adalimumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tofacitinib 5 mgBID x 12 months","type":"EXPERIMENTAL"},{"label":"Tofacitinib 10 mg BID x 12 months","type":"EXPERIMENTAL"},{"label":"Adalimumab 40 mg q2 weeks x 12 months","type":"ACTIVE_COMPARATOR"},{"label":"Placebo x3 months, then tofacitinib 5 mg BIDx 9 months","type":"PLACEBO_COMPARATOR"},{"label":"Placebo x 3 months, then tofacitinib 10 mg BID x 9 months","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying antirheumatic drug. Adalimumab is used as a comparator.","primaryOutcome":{"measure":"Percentage of Participants Meeting American College of Rheumatology Response Criteria â‰¥20% (ACR20): Month 3","timeFrame":"At end of Month 3","effectByArm":[{"arm":"Tofacitinib, 5 mg, Twice Daily","deltaMin":50.47,"sd":null},{"arm":"Tofacitinib, 10 mg, Twice Daily","deltaMin":60.58,"sd":null},{"arm":"Adalimumab, 40 mg, Every 2 Weeks","deltaMin":51.89,"sd":null},{"arm":"Placebo","deltaMin":33.33,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"0.0102"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"0.0055"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":5},"locations":{"siteCount":123,"countries":["United States","Australia","Belgium","Bulgaria","Canada","Czechia","France","Germany","Hungary","Mexico","Poland","Russia","Slovakia","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["40241921","39702318","37608391","36958766","36931693","36814062","36526796","36476498","36076054","36045453","35385361","35139908","34921355","34870800","34510295","34226183","33766074","32910531","32816215","32006348","31112005","31111255","30824647","30713721","30680661","30414064","30373651","29045212"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921091&StudyName=Efficacy%20And%20Safety%20Of%20Tofacitinib%20In%20Psoriatic%20Arthritis%3A%20Comparator%20Study"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":107},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Pharyngitis","Blood creatine phosphokinase increased"]}}